Nanocurcumin modulates Th17 cell responses in moderate and severe COPD patients
Amirhossein Mardi,
Samaneh Abdolmohammadi-Vahid,
Sarvin Alizadeh Sadeghi,
Sajad Jafarzadeh,
Sanaz Abbaspour-Aghdam,
Ali Hazrati,
Haleh Mikaeili,
Hamed Valizadeh,
Armin Sadeghi,
Majid Ahmadi,
Mehdi Nadiri
Affiliations
Amirhossein Mardi
Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Samaneh Abdolmohammadi-Vahid
Immunology Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Sarvin Alizadeh Sadeghi
Department of Internal Medicine, Clinical Research Development Center at Modarres Hospital, Tabriz of Medical Sciences, Tehran, Iran
Sajad Jafarzadeh
Department of Stem Cells and Developmental Biology, Cell Sciences Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Embryology Lab, East Azarbaijan ART Center, Tabriz, Iran
Sanaz Abbaspour-Aghdam
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Ali Hazrati
Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Haleh Mikaeili
Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Hamed Valizadeh
Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Armin Sadeghi
Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
Majid Ahmadi
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Corresponding author. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mehdi Nadiri
Tuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran; Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Corresponding author. Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory process in the airways that results in airflow obstruction. It is mainly linked to cigarette smoke exposure. Th17 cells have a role in the pathogenesis of COPD by secreting pro-inflammatory cytokines, which cause hyperinflammation and progression of the disease.This study aimed to assess the potential therapeutic effects of nanocurcumin on the Th17 cell frequency and its responses in moderate and severe COPD patients. This study included 20 patients with severe COPD hospitalized in an intensive care unit (ICU) and 20 patients with moderate COPD. Th17 cell frequency, Th17-related factors gene expression (RAR-related orphan receptor t (RORγt), IL-17, IL-21, IL-23, and granulocyte-macrophage colony-stimulating factor), and serum levels of Th17-related cytokines were assessed before and after treatment in both placebo and nanocurcumin-treated groups using flow cytometry, real-time PCR, and ELISA, respectively.According to our findings, in moderate and severe nanocurcumin-treated COPD patients, there was a substantial reduction in the frequency of Th17 cells, mRNA expression, and cytokines secretion level of Th17-related factors compared to the placebo group. Furthermore, after treatment, the metrics mentioned above were considerably lower in the nanocurcumin-treated group compared to before treatment.Nanocurcumin has been shown to decrease the number of Th17 cells and their related inflammatory cytokines in moderate and severe COPD patients. As a result, it might be used as an immune-modulatory agent to alleviate the patient's inflammatory state.
